Drilldown: Medicines

25B-NBOH (1) · 25B-NBOMe (1) · 25C-NBOH (1) · 25C-NBOMe (1) · 25I-NBOH (1) · 25I-NBOMe (1) · 25N-NBOMe (1) · 2C-B (1) · 2C-B-FLY (1) · 2C-C (1) · 2C-D (1) · 2C-E (1) · 2C-I (1) · 2C-P (1) · 2C-T-2 (1) · 2C-T-7 (1) · Allylescaline (1) · Bromo-DragonFLY (1) · Ciclopirox (1) · Clotrimazole (1) · DOB (1) · DOC (1) · DOI (1) · DOM (1) · Escaline (1) · Ketoconazole (1) · Methallylescaline (1) · Proscaline (1) · TMA-2 (1)

None (25) · Lotrimin, Mycelex, Gyne-Lotrimin; OTC widely (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) · Nizoral (oral discontinued in US for most fungal indications; topical still widely available) (1) · Penlac (nail lacquer), Loprox (cream/lotion/shampoo) (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

None (2) · 5-HT2A agonist (12) · 5-HT2A agonist; long duration (1) · 5-HT2A agonist; MAO inhibitor (1) · 5-HT2A agonist; milder than other 2C-x (1) · 5-HT2A partial agonist (1) · Extremely potent 5-HT2A agonist; vasoconstrictor (1) · Extremely potent 5-HT2A agonist; very long duration (1) · Potent 5-HT2A agonist (5) · Potent 5-HT2A agonist; no oral activity (1) · Potent 5-HT2A agonist; very long duration (1) · Very potent 5-HT2A agonist; long duration (1) · '"`UNIQ--vote-00001233-QINU`"' Onychomycosis cure rates with nail lacquer are modest (mycologic cure ~30-50%, complete cure ~5-12% at 48 weeks); oral terbinafine remains substantially more effective when systemic therapy is acceptable'"`UNIQ--ref-00001234-QINU`"'. (1)

None (26) · '"`UNIQ--vote-00000884-QINU`"', '"`UNIQ--vote-00000885-QINU`"', '"`UNIQ--vote-00000886-QINU`"', '"`UNIQ--vote-00000887-QINU`"' (1) · '"`UNIQ--vote-00000F40-QINU`"', '"`UNIQ--vote-00000F41-QINU`"', '"`UNIQ--vote-00000F42-QINU`"', '"`UNIQ--vote-00000F43-QINU`"', '"`UNIQ--vote-00000F44-QINU`"' (1) · '"`UNIQ--vote-00001235-QINU`"', '"`UNIQ--vote-00001236-QINU`"', '"`UNIQ--vote-00001237-QINU`"', '"`UNIQ--vote-00001238-QINU`"' (1)

None (26) · Topical 2% shampoo twice weekly for seborrheic dermatitis or tinea versicolor; oral use restricted by 2013 FDA action to indications where alternatives have failed (1) · Topical cream/lotion BID; shampoo twice weekly; nail lacquer (Penlac) once daily for up to 48 weeks (1) · Topical: 1% cream BID × 2-4 weeks; vaginal: 1% or 2% cream nightly × 7 days, or 100/200/500 mg vaginal tablet single or 3-day regimens; troche: 10 mg PO five times daily × 2 weeks for thrush (1)

None (26) · 0.77% topical cream, lotion, suspension; 1% shampoo; 8% nail lacquer (Penlac) (1) · 1% (OTC), 2% (Rx) shampoo; 2% cream; 2% gel; 200 mg oral tablet (rarely used now) (1) · 1% topical cream, lotion, solution; 1%, 2% vaginal cream; 100, 200, 500 mg vaginal tablets; 10 mg oral troches; combination with betamethasone (Lotrisone, Rx) (1)

None (26) · BID topical; once daily nail lacquer (1) · Topical: BID; troche: 5×/day (1) · Topical: regimen-specific; oral: 400 mg/d in remaining specialty indications (1)

None (25) · gel); oral (restricted) (1) · insufflated (1) · Oral (1) · oral troche (1) · PR (1) · shampoo (1) · Topical (2) · Topical (cream (1) · vaginal (1)

None (25) · 45-75 min (oral) (1) · Days (1) · Days for dermatophyte clearance; nail clearance over months (1) · Topical hours; oral days (1)

None (25) · 4-8 h (1) · Hours per application (2) · Hours per application (topical); 24 hours (oral) (1)

None (25) · Not meaningfully described (minimal systemic absorption from topical use)'"`UNIQ--ref-00000F45-QINU`"' (1) · Not meaningfully described (topical local action)'"`UNIQ--ref-00001239-QINU`"' (1) · Not well characterized (1) · Topical: not meaningfully described; oral 2-8 hours'"`UNIQ--ref-00000888-QINU`"' (1)

None (25) · Not well characterized (1) · Topical with minimal systemic absorption'"`UNIQ--ref-0000123A-QINU`"' (1) · Topical: minimal systemic; oral: pH-dependent, requires gastric acid'"`UNIQ--ref-00000889-QINU`"' (1) · Topical: minimal systemic; troche: ~3% systemic'"`UNIQ--ref-00000F46-QINU`"' (1)

None (25) · Generally considered safe (minimal systemic absorption).<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Not established (1) · Topical and vaginal generally considered safe; widely used.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Topical generally safe; oral avoided.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

None (25) · OTC (1% shampoo) and [[USLegal:Prescription only|Rx-only]] (higher strengths, oral) in US. Oral form carries a '''Boxed Warning''' for hepatotoxicity and is restricted by FDA to refractory fungal infections where no alternatives are available (1) · OTC (lower strengths) and [[USLegal:Prescription only|Rx-only]] (combination with betamethasone) in US (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1) · [[USLegal:Prescription only|Rx-only]] in US (1)